One of these companies analyses your waste from a device clipped to your toilet. Another just became the most valuable healthcare AI company on earth. Both raised money in the last few months, and the gap between them tells you exactly where healthtech is heading.
Here are five recent healthtech raises worth knowing, and the one pattern that connects all of them.
The backdrop matters. US digital health startups pulled in $4 billion in the first quarter of 2026 alone, the strongest opening quarter since the pandemic peak, and most of that money landed on a small group of companies doing one thing extremely well. These five are a clean cross-section of where it went.
1. Throne: an AI device that turns your toilet into a health checkpoint
$4M seed, led by Moxxie Ventures, with Lance Armstrong and WHOOP's co-founder among the angels
Throne builds a device that mounts onto a normal toilet and uses computer vision to scan your waste for early signs of gut, kidney and urological conditions. The product started as a poker-night joke and is still pre-launch, but it pulled in $4 million and a roster of backers that includes Lance Armstrong and WHOOP co-founder John Capodilupo, who joined as chief product officer.
It is the least glamorous data source in your house, and possibly the most honest one.
Why it matters: Preventive care only works when the screening happens on its own, and nothing is more automatic than a toilet.
2. OpenEvidence: the AI doctors actually pull up at the bedside
$250M Series D at a $12B valuation, co-led by Thrive Capital and DST Global
OpenEvidence is an AI medical search engine trained only on peer-reviewed literature, giving doctors citation-linked answers at the point of care. Its January round doubled the valuation to $12 billion, making it the most valuable healthcare AI company in the world. It is already used by roughly 40% of US physicians, more than every other AI tool for doctors combined.
When one product is used by nearly half the doctors in a country, it stops being a tool and becomes infrastructure.
Why it matters: Whoever sits between a clinician and the evidence quietly shapes what gets prescribed for everyone.
3. Apella: ambient AI that runs the busiest room in the hospital
$80M Series B, led by HighlandX
Apella puts computer vision into the operating room, automatically logging up to 14 surgical events and writing the data straight into the medical record. Hospitals using it report a 5% rise in surgical volume without adding staff or space. That lands hard because the operating room can drive up to 60% of a hospital's revenue.
It does not help the surgeon cut. It helps the hospital fit more surgeries into the same day.
Why it matters: The fastest financial win in healthcare right now is not a new drug, it is a less wasted hour.
4. Midi Health: virtual care for the part of women's health medicine forgot
$100M Series D at a $1B valuation, led by Goodwater Capital
Midi started with perimenopause and menopause, two of the most dismissed areas in medicine, and built a national virtual clinic around them. Its February round made it a unicorn, backed by Goodwater Capital and Serena Williams' Serena Ventures. The company now operates across 50 states and works with insurers covering 45 million women.
It built a billion-dollar company out of a complaint women had been told to simply live with.
Why it matters: The biggest untapped markets in health are often the ones medicine quietly ignored for decades.
5. Talkiatry: real psychiatrists, employed and scaled with AI underneath
$210M Series D, led by Perceptive Advisors, with a16z participating
Talkiatry employs more than 800 full-time psychiatrists and runs the back office on a proprietary AI layer that handles scheduling, billing and engagement. Its February round pushed total funding past $400 million. The group has delivered 3 million patient visits and reports 87% of anxiety patients improving after just two sessions.
It bet that the future of mental health is not a chatbot, but a real doctor with the admin lifted off their plate.
Why it matters: The winning AI health model may be humans doing the care and machines doing the paperwork.
Notice what is missing from this list
No general chatbot. No platform promising AI for everything. Every company here picked one specific, unglamorous corner of healthcare and went deep into it. Your gut. The operating room. Menopause. Psychiatry. The medical literature.
Each one owns data nobody else has and a workflow nobody else wants to rebuild. That is the pattern, and it is the whole point. The money in healthtech is moving away from thin apps and toward companies that do the actual work inside one narrow lane.
It is also why nearly 60% of last quarter's healthtech funding went to just a dozen companies. Investors are not spreading small bets across clever apps anymore. They are concentrating on the few businesses buried so deep in one workflow that they become almost impossible to rip out.
If you are building or investing in this space, the signal is loud. Narrow and deep is beating broad and shiny.
So here is my question. Of these five, which is solving a real problem, and which is a feature dressed up as a company? Tell me which one you would back with your own money. Drop it below, and I read every comment.